HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Positive 57.0%

Neg 0% Neu 0% Pos 57%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and raises the price target from $50 to $60.